Acta Scientific Neurology (ASNE) (ISSN: 2582-1121)

Review Article Volume 3 Issue 10

Neurobiochemical Crosstalk between COVID-19 and Alzheimer’s Disease

Mohammad Azizur Rahman1*, Kamrul Islam1, Saidur Rahman2 and Al Amin3

1Department of Biochemistry and Molecular Biology, Jahangirnagar University, Savar, Dhaka, Bangladesh
2Department of Chemistry, Jahangirnagar University, Savar, Dhaka, Bangladesh
3Global Center for Environmental Remediation (GCER), The University of Newcastle, Callaghan, NSW, Australia

*Corresponding Author: Mohammad Azizur Rahman, Department of Biochemistry and Molecular Biology, Jahangirnagar University, Savar, Dhaka, Bangladesh.

Received: August 19, 2020; Published: September , 2020



  COVID-19, the global threat to the humanity, shares etiological cofactors with multiple diseases including Alzheimer’s disease (AD). Understanding the common links between COVID-19 and AD would harness strategizing therapeutic approaches against both. Considering the urgency of formulating COVID-19 medication, its AD association and manifestations have been reviewed here, putting emphasis on memory and learning disruption. COVID-19 and AD share common links with respect to angiotensin-converting enzyme 2 (ACE2) receptors, proinflammatory markers such as interleukin-1 (IL-1), IL-6, cytoskeleton-associated protein 4 (CKAP4), galactein-9 and APOE4 allele. Common etiological factors and common manifestations described in this review would aid in developing therapeutic strategies for both COVID-19 and AD and thus impact on eradicating the ongoing global threat. Thus, people suffering from COVID-19 or who have come round of it as well as people at risk of developing AD or already suffering from AD, would be benefitted.

Keywords: ACE2; ApoE4; Gal-9; Inflammation; Neuroinvasive



  1. Desforges M., et al. “Human coronaviruses and other respiratory viruses: underestimated opportunistic pathogens of the central nervous system?” Viruses1 (2019): 14.
  2. Asadi-Pooya AA and Simani L. “Central nervous system manifestations of COVID-19: a systematic review”. Journal of the Neurological Sciences 413 (2020): 116832.
  3. Mao L., et al. “Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China”. JAMA Neurology 6 (2020): 1-9.
  4. Fotuhi M., et al. “Neurobiology of COVID-19”. Journal of Alzheimer's Disease 1 (2020): 3-19.
  5. Hardy JA and Higgins GA. “Alzheimer’s disease: the amyloid cascade hypothesis”. Science5054 (1992): 184.
  6. Baig AM., et al. “Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host-virus interaction, and proposed neurotropic mechanisms”. ACS Chemical Neuroscience 7 (2020): 995-998.
  7. Li YC., et al. “The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients”. Journal of Medical Virology 6 (2020): 552-555.
  8. Wrapp D., et al. “Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation”. Science 6483 (2020): 1260-1263.
  9. Bridwell R., et al. “Neurologic complications of COVID-19”. American Journal of Emergency Medicine 7 (2020): 1549-1549.
  10. Sheraton M., et al. “A review of neurological complications of COVID-19”. Cureus 5 (2020): e8192.
  11. Steardo L., et al. “Neuroinfection may contribute to pathophysiology and clinical manifestations of COVID-19”. Acta Physiologica 3 (2020): e13473.
  12. Wu Y., et al. “Nervous system involvement after infection with COVID-19 and other coronaviruses”. Brain, Behavior, and Immunity 87 (2020): 18-22.
  13. Kabbani N and Olds JL. “Does COVID19 infect the brain? if so, smokers might be at a higher risk”. Molecular Pharmacology5 (2020): 351-353.
  14. Whittaker A., et al. “Neurological Manifestations of COVID-19: a systematic review and current update”. Acta Neurologica Scandinavica 1 (2020): 14-22.
  15. Hartung H and Aktas O. “COVID-19 and management of neuroimmunological disorders”. Nature Reviews Neurology 16 (2020): 347-348.
  16. Varatharaj A., et al. “Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study”. The Lancet Psychiatry (2020).
  17. Lahiri D and Ardila A. “COVID-19 pandemic: a neurological perspective”. Cureus4 (2020): e7889.
  18. Cojocaru IM., et al. “Study of interleukin-6 production in Alzheimer's disease”. Romanian Journal of Internal Medicine 1 (2011): 55-58.
  19. Motta M., et al. “Altered plasma cytokine levels in Alzheimer's disease: correlation with the disease progression”. Immunology Letters 1 (2007): 46-51.
  20. Bialuk I., et al. “IL-6 deficiency alters spatial memory in 4- and 24-month-old mice”. Neurobiology of Learning and Memory 155 (2018): 21-29.
  21. Chen X., et al. “Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely correlated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients”. Clinical Infectious Diseases (2020): ciaa 449.
  22. Wang H., et al. “Multiple enzyme release, inflammation storm and hypercoagulability are prominent indicators for disease progression in COVID-19: a multi-centered, correlation study with CT imaging score (2020).
  23. Ulhaq Z S and Soraya GV. “Interleukin-6 as a potential biomarker of COVID-19 progression”. Medecine et Maladies Infectieuses4 (2020): 382-383.
  24. Patel H., et al. “Proteomic blood profiling in mild, severe and critical COVID-19 patients”. Med Rxiv (2020).
  25. Zhang C., et al. “The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist tocilizumab may be the key to reduce the mortality”. The International Journal of Antimicrobial Agents 5 (2020): 105954.
  26. Hüll M., et al. “Interleukin-6-associated inflammatory processes in Alzheimer's disease: new therapeutic options”. Neurobiology of Aging 5 (1996): 795-800.
  27. Raphaël C., et al. “Early IL-1 receptor blockade in severe inflammatory respiratory failure complicating COVID-19”. Proceedings of the National Academy of Sciences of the United States of America32 (2020): 18951-18953.
  28. Giulio C., et al. “”. Lancet Rheumatology 2 (2020): e325-e331.
  29. Griffin WS., et al. “Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease”. Proceedings of the National Academy of Sciences of the United States of America 19 (1989): 7611-7615.
  30. Pugh RC., et al. “The immune system and memory consolidation: a role for the cytokine IL-1beta”. Neuroscience and Biobehavioral Reviews 1 (2001): 29-41.
  31. Sheng JG., et al.In vivo and In vitro evidence supporting a role for the inflammatory cytokine interleukin-1 as a driving force in Alzheimer pathogenesis”. Neurobiology of Aging5 (1996): 761-766.
  32. Depino AM., et al. “Learning modulation by endogenous hippocampal IL-1: blockade of endogenous IL-1 facilitates memory formation”. Hippocampus4 (2004): 526-535.
  33. Lu X., et al. “Galectin-9 ameliorates respiratory syncytial virus-induced pulmonary immunopathology through regulating the balance between Th17 and regulatory T cells”. Virus Research 195 (2015): 162-171.
  34. Caniglia JL., et al. “A potential role for galectin-3 inhibitors in the treatment of COVID-19”. Peer Journal 8 (2020): e9392.
  35. Rinaldi M., et al. “Galectin-1 circumvents lysolecithin-induced demyelination through the modulation of microglial polarization/phagocytosis and oligodendroglial differentiation”. Neurobiology of Disease 96 (2016): 127-143.
  36. Wang X., et al. “Elevated galectin-3 levels in the serum of patients with Alzheimer's Disease”. American Journal of Alzheimer's Disease and Other Dementias 8 (2015): 729-732.
  37. Tao CC., et al. “Galectin-3 promotes Aβ oligomerization and Aβ toxicity in a mouse model of Alzheimer's disease”. Cell Death and Differentiation1 (2020): 192-209.
  38. Cancino GI., et al. “p63 Regulates adult neural precursor and newly born neuron survival to control hippocampal-dependent behavior”. Journal of Neuroscience 31 (2013): 12569-12585.
  39. Kazi AS., et al. “Role of the PI3-kinase signaling pathway in trafficking of the surfactant protein A receptor P63 (CKAP4) on type II pneumocytes”. The American Journal of Physiology-Lung Cellular and Molecular Physiology 6 (2010): L794-L807.
  40. Yanagita K., et al. “Cytoskeleton-associated protein 4 is a ovel serodiagnostic marker for lung cancer”. The American Journal of Pathology 6 (2018): 1328-1333.
  41. Hultman K., et al. “The APOE ɛ4/ɛ4 genotype potentiates vascular fibrin(ogen) deposition in amyloid-laden vessels in the brains of Alzheimer's disease patients”. Journal of Cerebral Blood Flow and Metabolism 8 (2013): 1251-1258.
  42. Beeri MS., et al. “Coronary artery disease is associated with Alzheimer disease neuropathology in APOE4 carriers”. Neurology9 (2006): 1399-1404.
  43. Kuo CL., et al. “APOEe4 genotype predicts severe COVID-19 in the UK Biobank community cohort”. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences (2020): glaa131.
  44. Lim KH., et al. “Elevation of ACE2 as a SARS-CoV-2 entry receptor gene expression in Alzheimer's disease”. Journal of Infection 3 (2020): e33-e34.
  45. Susswein AJ., et al. “Nitric oxide and memory”. Neuroscientist 10 (2004): 153-162.
  46. Alkeridy WA., et al. “A unique presentation of delirium in a patient with otherwise asymptomatic COVID-19”. Journal of the American Geriatrics Society (2020): 10.1111.




Citation: Mohammad Azizur Rahman., et al. “Neurobiochemical Crosstalk between COVID-19 and Alzheimer’s Disease". Acta Scientific Neurology 3.10 (2020): .


Acceptance rate32%
Acceptance to publication20-30 days
Impact Factor0.844

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is May 20, 2021.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US